BioVentrix Inc.

Oct 08, 2019

BioVentrix Enrolls and Treats First Patient in REVIVE-HF European RCT for Ischemic Heart Failure Patients

Sep 23, 2019

BioVentrix Announces Study Design for REVIVE-HF: Randomized Controlled Trial (RCT) in Europe

Sep 16, 2019

BioVentrix Announces the Appointment of Pedro Marques as VP of Sales in Europe

Aug 06, 2019

BioVentrix Announces Key Additions to Leadership Team

Feb 28, 2019

BioVentrix Achieves 2019 NUB Reimbursement Status 1 in Germany for Revivent TC(TM) TransCatheter Ventricular Enhancement System

Mar 12, 2018

BioVentrix Announces First Patient at Cardiovascular Institute of the South Successfully Treated in IDE Study of Revivent TC(TM) TransCatheter Ventricular Enhancement Treatment

Feb 06, 2018

BioVentrix Achieves 2018 NUB Reimbursement Status 1 in Germany for Revivent TC(TM) TransCatheter Ventricular Enhancement System

Oct 27, 2017

BioVentrix Announces Scheduled Presentations at Transcatheter Cardiovascular Therapeutics 2017

Oct 04, 2017

BioVentrix Announces First Patient Enrolled in the U.S. arm of IDE Study of the Revivent TC(TM) TransCatheter Ventricular Enhancement Treatment

Sep 18, 2017

BioVentrix announces the 1st Revivent TC(TM) TransCatheter Ventricular Enhancement procedure for Ischemic Cardiomyopathy treatment at the University Heart Center Zurich in Switzerland

Aug 21, 2017

BioVentrix Announces First Patient Enrolled in IDE Study of the Revivent TC(TM) TransCatheter Ventricular Enhancement Treatment for Ischemic Cardiomyopathy